AR110250A1 - Formulación tópica que comprende n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida - Google Patents
Formulación tópica que comprende n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamidaInfo
- Publication number
- AR110250A1 AR110250A1 ARP170103303A ARP170103303A AR110250A1 AR 110250 A1 AR110250 A1 AR 110250A1 AR P170103303 A ARP170103303 A AR P170103303A AR P170103303 A ARP170103303 A AR P170103303A AR 110250 A1 AR110250 A1 AR 110250A1
- Authority
- AR
- Argentina
- Prior art keywords
- methyl
- pyridinyl
- acetamide
- phenyl
- thiazol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Formulaciones farmacéuticas de agentes antivirales activos para el uso en aplicación tópica, particularmente para el uso de estos en el tratamiento de infecciones por virus herpes humano, en donde los agentes antivirales activos pueden seleccionarse del grupo que comprende el hemihidrato de la base libre de N-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-N-metil-2-[4-(2-piridinil)-fenil]-acetamida, la sal maleato de N-[5-(amino-sulfonil)-4-metil-1,3-tiazol-2-il]-N-metil-2-[4-(2-piridinil)fenil]acetamida, la sal de mesilato de N-[5-(amino-sulfonil)-4-metil-1,3-tiazol-2-il]-N-metil-2-[4-(2-piridinil)fenil]acetamida, y la base libre de N-[5-(amino-sulfonil)-4-metil-1,3-tiazol-2-il]-N-metil-2-[4-(2-piridinil)fenil]acetamida. Dichas formulaciones comprenden un agente antiviral como se ha descrito anteriormente en estado disuelto o en forma solubilizada, hidroxil tolueno butilado (BHT) y PEG 400 Super RefinedTM a un pH aparente de 4,0 a 5,0, preferiblemente a un pH aparente de 4,0 a 4,5.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16201005 | 2016-11-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR110250A1 true AR110250A1 (es) | 2019-03-13 |
Family
ID=57406185
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP170103303A AR110250A1 (es) | 2016-11-28 | 2017-11-28 | Formulación tópica que comprende n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida |
Country Status (4)
Country | Link |
---|---|
AR (1) | AR110250A1 (es) |
TW (1) | TW201825095A (es) |
UY (1) | UY37497A (es) |
WO (1) | WO2018095576A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MD3692039T2 (ro) | 2017-10-05 | 2023-05-31 | Innovative Molecules Gmbh | Enantiomerii tiazolilor substituiți ca compuși antivirali |
TW202038947A (zh) | 2018-11-28 | 2020-11-01 | 德商創新分子有限責任公司 | 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑 |
EP3925595A1 (en) * | 2020-06-17 | 2021-12-22 | AiCuris GmbH & Co. KG | Ophthalmic formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl] acetamide hemihydrate |
US20230124969A1 (en) | 2020-03-26 | 2023-04-20 | Aicuris Gmbh & Co. Kg | Ophthalmic formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3- thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide hemihydrate |
AU2021300110A1 (en) * | 2020-06-30 | 2023-02-02 | Dermira, Inc. | IRAK4 inhibitors and topical uses thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DOP2000000109A (es) | 1999-12-23 | 2002-08-30 | Gerald Kleymann | Derivados de tiazolilamida |
DE10129714A1 (de) | 2001-06-22 | 2003-01-02 | Bayer Ag | Topische Anwendung von Thiazolylamiden |
DE10129716A1 (de) * | 2001-06-22 | 2003-01-02 | Bayer Ag | Kombinationspräparate zur Herpes-Behandlung |
DE102005014248A1 (de) | 2005-03-30 | 2006-10-05 | Aicuris Gmbh & Co. Kg | Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid |
DK2563374T3 (da) * | 2010-07-08 | 2014-01-20 | Devirex Ag | Polyethylenglycolsammensætninger til kontrol af tilbagefald af herpes labialis, herpes genitalis og herpes zoster |
EP2573086A1 (en) | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate |
EP2573085A1 (en) | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range |
-
2017
- 2017-11-28 AR ARP170103303A patent/AR110250A1/es unknown
- 2017-11-28 WO PCT/EP2017/001397 patent/WO2018095576A1/en active Application Filing
- 2017-11-28 TW TW106141481A patent/TW201825095A/zh unknown
- 2017-11-28 UY UY0001037497A patent/UY37497A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
UY37497A (es) | 2018-06-29 |
TW201825095A (zh) | 2018-07-16 |
WO2018095576A1 (en) | 2018-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR110250A1 (es) | Formulación tópica que comprende n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida | |
CL2018003291A1 (es) | Amidas heterocíclicas útiles como moduladores de proteínas (divisional de solicitud cl 2850-2018). | |
AR110249A1 (es) | Hemihidrato de la base libre de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, métodos de fabricación y usos del mismo | |
CR20170411A (es) | Composiciones farmacéuticas que comprenden n-(3,5-dimetoxifenil)-n-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il-quin oxalin-6-il]etano-1,2-diamina | |
CL2017000287A1 (es) | 2-(morfolin-4-il)-1,7-naftiridinas. | |
NI201700073A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
DOP2017000270A (es) | Composiciones farmacéuticas tópicas | |
CO2021000174A2 (es) | Composiciones tópicas para el alivio del dolor | |
CL2018000033A1 (es) | Composición para destapar una nariz tapada que tiene actividad antiviral. | |
BR112013006953A2 (pt) | composto, composições farmacêutica e anti-helmíntica, uso de um composto, kit, e, método de tratamento de uma doença | |
AR073801A1 (es) | Emulsiones de liberacion modificadas para aplicacion en la piel o mucosa vaginal | |
PE20191650A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue | |
MA56547A (fr) | Formulations d'agents pénétrants transdermiques contenant du cannabidiol | |
BR112022010891A2 (pt) | Combinação de um antagonista do receptor lpa1 de azetidina com agentes antifibróticos | |
EA201990765A1 (ru) | Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок | |
UY37498A (es) | Una sal maleato de la base libre de n-[5-(aminosulfonil)-4-20 metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, formulaciones farmacéuticas, métodos de fabricación y usos de la misma | |
BR112017022521A2 (pt) | agente para controlar doenças em plantas de cereais, método para controlar doenças em plantas de cereais, uso de fluoroimida ou um sal agroquimicamente aceitável da mesma, uso de um ou mais compostos, e uso de fluoroimida ou um sal agroquimicamente aceitável da mesma | |
PE20181522A1 (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer | |
CO2024004745A2 (es) | Formas cristalinas de derivados de quinazolina, preparación, composición y uso de estas | |
RS54420B1 (en) | FORMULATION CONTAINING PHENYLAMINOPYRIMIDINE DERIVATIVE AS ACTIVE INGREDIENT | |
PE20181369A1 (es) | Suspensiones orales acuosas fisica y quimicamente estables de givinostat | |
CL2020000221A1 (es) | Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial. | |
AR086491A1 (es) | Composicion farmaceutica que comprende fexofenadina | |
MX2023006235A (es) | Composiciones para administracion de farmacos y metodos de uso de las mismas. | |
BR112018007399A2 (pt) | composição, método de tratamento, kit de partes e forma de dosagem |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |